Board of Directors

P. Sherrill Neff has been a member of our Board of Directors since March 2004 and has served as Chairman of the Board since February 2008. Mr. Neff is a founding partner of and has served as a managing partner of Quaker BioVentures, a venture capital firm, since 2002. From 1994 to 2002, Mr. Neff was President, Chief Operating Officer, and a Director of Neose Technologies, Inc., a publicly traded life sciences company. Mr. Neff currently serves as a Director of Resource Capital Corp. and Amicus Therapeutics, Inc. Mr. Neff received his B.A. in Religion from Wesleyan University and his J.D. from the University of Michigan Law School.

W. Thomas Amick has been a member of our Board of Directors since March 2004. Mr. Amick currently serves as Chairman of the board of Aldagen, Inc., a privately held biotech company. From February 1974 to February 2004, Mr. Amick served in a series of positions with Johnson & Johnson, including Vice President, Business Development of the Johnson & Johnson Development Corporation, President of Ortho Biotech Europe, President of Janssen-Ortho, and Vice President of the Oncology Franchise for Ortho Biotech Products, L.P. Mr. Amick currently serves as a member of the Advisory Board for Intersouth Partners and Quaker BioVentures and is on the Boards of Directors of Argolyn Pharmaceuticals and Transport Pharmaceuticals and is Chairman of the board of Discovery Laboratories, Inc. Mr. Amick received his B.S. in Business Administration from Elon University.

Kevin J. Bitterman, Ph.D., has served on our Board of Directors since December 2007. Dr. Bitterman is a principal with Polaris Venture Partners and is a co-founder of Sirtris Pharmaceuticals. Dr. Bitterman received his Ph.D. from Harvard Medical School and a B.A. from Rutgers College with a major in Biological Sciences and a minor in Philosophy.

David L. Castaldi has been a member of our Board of Directors since May 2004. Mr. Castaldi has worked as an independent consultant for the biotechnology and pharmaceutical industry since December 1994. Previously, Mr. Castaldi founded and served as Chief Executive Officer and as a director of two life science companies and served as President of Baxter International’s therapeutic biologics division. Mr. Castaldi currently serves as a Director of Nabi Biopharmaceuticals. Mr. Castaldi received his B.A. in Business from the University of Notre Dame and his M.B.A. from the Harvard Business School.

Dennis Dougherty has been a member of our Board of Directors since October 1998. Mr. Dougherty is the founding general partner of Intersouth Partners, a venture capital firm, which was founded in 1985. Mr. Dougherty earned his B.A. in Business from Oklahoma City University.

Jeffrey Leiden, M.D., Ph.D., has been a member of our Board of Directors since October 2008.  Dr. Leiden is Managing Director of Clarus Ventures, a life sciences venture capital firm.  From 2000 to 2006 Dr. Leiden was President and COO of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Abbott Board of Directors and the TAP Board of Directors.  Previously, Dr. Leiden held several academic appointments including Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School.  Dr. Leiden is a member of the Board of Directors of Shire Pharmaceuticals Group plc.  Dr. Leiden received both his medical degree and PhD from the University of Chicago and an honorary MA from Harvard University.

Liza Page Nelson has been a member of our Board of Directors since March 2008. Ms. Nelson joined Investor Growth Capital in 1998 and serves as Managing Director and Co-Head of the firm’s healthcare group. Previously, Ms. Nelson served in a series of positions over a ten-year period with Pfizer in the areas of corporate finance / mergers and acquisitions, strategy, business development, marketing and operating management. Ms. Nelson also worked for Boston Consulting Group and E.M. Warburg, Pincus and Co. Ms. Nelson holds an M.B.A. in Finance and Marketing from the Yale School of Management and a B.A. in Economics from Wesleyan University in Middletown, Connecticut.

Jan Turek has been our President and Chief Executive Officer and a member of our Board of Directors since June 2001. From 1996 to 2001, Mr. Turek served as Senior Vice President and General Manager for the Biological Products business unit of Bayer Corporation, a unit dedicated to therapeutic proteins. Mr. Turek has also held positions at Bristol Myers Squibb Co. and Sandoz Inc. Mr. Turek currently serves on the board of directors of Southeast BIO and is Co-Chair of the Emerging Companies Forum of the North Carolina Biosciences Organization. Mr. Turek received his B.S. in Biochemistry from McGill University in Montreal, Canada.

Klaus Veitinger, M.D., has been a member of the Board of Directors since October 2008.  Dr. Veitinger has been a Venture Partner with OrbiMed Advisors, a life sciences and healthcare-dedicated investment firm, since 2007.  From 2000 to 2006 he was a Member of the Executive Board of Schwarz Pharma AG and the Chief Executive Officer of Schwarz Pharma Inc. where he was responsible for the U.S. and Asia businesses.  Dr. Veitinger earned his medical degree and his doctorate (Ph.D.) in pathophysiology from the University of Heidelberg and his MBA at INSEAD in France.

Return to top